Related Experiment Video
Updated: Jan 31, 2026

ATAC-Seq Optimization for Cancer Epigenetics Research
Published on: June 30, 2022
Epigenetic Targets and their Inhibitors in Cancer Therapy
Le Zhao1,2, Yong-Tao Duan3, Ping Lu1
1College of pharmacy, Henan University of Chinese Medicine, Zhengzhou, China.
Abstract:
Epigenetics is defined as the stable and heritable alternations in gene expression without changing the DNA nucleotide sequence. The initiation and progression of cancer result from not only genetic mutation, but also aberrant epigenetic regulation, such as DNA methylation and histones acetylation. Although Genetic alternations cannot be reversed, epigenetic modification is a dynamic and reversible process. Over the past few decades, much progress has been made in the research of epigenetic medications and a variety of drugs have been developed targeting at epigenetic regulatory proteins, which are capable of restoring malignant cancer cells to the normal state. The epigenetic drugs currently approved for cancer treatment mainly target at DNA methylation and histones acetylation. In addition, there are a great many epigenetic drugs in clinical trials for cancer therapy, such as inhibitors of DNA methyltransferases, histone deacetylases, histone methyltransferases, lysine specific demethylases, and BET (bromodomain and extra-terminal domain) family proteins. We will discuss the latest developments of these inhibitors and their applications in cancer therapy.
Insights
Epigenetic modifications, unlike genetic mutations, are reversible and offer new cancer treatment avenues. Research focuses on epigenetic drugs targeting DNA methylation and histone acetylation to restore normal cell function.
Area of Science:
- Molecular Biology
- Oncology
- Pharmacology
Background:
- Cancer development involves genetic mutations and epigenetic dysregulation.
- Epigenetic mechanisms like DNA methylation and histone acetylation are crucial in cancer.
- Epigenetic modifications are reversible, offering therapeutic potential.
Purpose of the Study:
- To review the latest developments in epigenetic drugs for cancer therapy.
- To discuss the application of epigenetic inhibitors in cancer treatment.
Main Methods:
- Review of current epigenetic drugs and clinical trials.
- Focus on inhibitors targeting DNA methylation and histone acetylation.
- Exploration of novel epigenetic drug targets including BET proteins.
Main Results:
- Approved epigenetic drugs primarily target DNA methylation and histone acetylation.
- Numerous epigenetic drugs are in clinical trials targeting various epigenetic regulators.
- Inhibitors of DNA methyltransferases, histone deacetylases, and BET proteins show promise.
Conclusions:
- Epigenetic drugs represent a promising and reversible therapeutic strategy for cancer.
- Targeting epigenetic modifications offers a new paradigm in cancer treatment.
- Ongoing research and clinical trials are expanding the scope of epigenetic therapies.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Gene Therapy

